Pharmaceutical

Europe’s TCR immunotherapy licensing deals surge 123% above US in 2024

TCR immunotherapy is emerging as a promising, targeted approach for treating solid tumours and other indications.

Nov 23, 2024 - 06:00
Europe’s TCR immunotherapy licensing deals surge 123% above US in 2024
TCR immunotherapy is emerging as a promising, targeted approach for treating solid tumours and other indications.
Read the original article

Tags:

Previous Article

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

Next Article

Enveda raises $130m to advance AI-driven plant based drug development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Prodrugs and patents: Enhancing therapy adherence and reducing side effects 

Prodrugs and patents: Enhancing therapy adherence and r...

Sep 12, 2024

Jazz Pharma’s Enrylaze wins European approval for AML and LBL

Jazz Pharma’s Enrylaze wins European approval for AML a...

Sep 23, 2023

Eight evolving patient communication risks in pharma and biotech

Eight evolving patient communication risks in pharma an...

Dec 14, 2023